The planned withdrawal follows the January failure of a Phase III trial to back up the study used for Lartruvo's accelerated approval. Following the announcement, the FDA and EMA recommended no new patients receive the drug.
Lilly announced last week that the Phase III confirmatory trial for Lartruvo in soft-tissue sarcomas failed to confirm the benefit seen in the Phase II study that led to its accelerated approval.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
A Phase III trial of Lartruvo, which won accelerated approval for soft-tissue sarcoma in 2016, failed to confirm an overall survival benefit.